Compare Kinder Morgan Inc (KMI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Tango Therapeutics Inc. — how do they compare? Kinder Morgan Inc trades at $33.37 (market cap $74.44B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Kinder Morgan Inc is far larger — about 19.9× Tango Therapeutics Inc.'s market cap, and Kinder Morgan Inc pays a 3.53% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 151 Days and Tango Therapeutics Inc. for 0 Days on average.
| KMI | TNGX | |
|---|---|---|
Market Cap | $74.44B | $3.75B |
Volume | 10,771,998 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $34.31 | $32.90 |
52-Week Low | $25.84 | $7.50 |
Typical Hold Time | 151 Days | 0 Days |
Enterprise Value | $106.49B | $2.77B |
Dividend Yield | 3.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $33.35, up 0.82% with a bullish technical outlook. The company delivered three consecutive earnings beats in 2026, with Q3 results pending. Revenue grew to $16.94B in 2025, while net income reached $3.06B. Analyst consensus is mixed with a $37.20 price target, representing 11.5% upside. Recent news highlights the company's $6B-$7B growth pipeline and resilience amid energy market volatility.
KMI offers income investors a compelling opportunity with strong cash flows and a visible growth backlog, though elevated debt levels and energy market sensitivity present risks. The stock's current valuation appears reasonable relative to peers, with technical indicators supporting near-term bullish momentum.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
